Guselkumab in moderate to severe psoriasis in routine clinical care: an Italian 44-week real-life experience

A case of erythrodermic psoriasis successfully treated with guselkumab

(2020) Matteo Megna et al.   Dermatologic Therapy

Effectiveness and short‐term (16‐week) tolerance of guselkumab for psoriasis under real‐life conditions: a retrospective multicenter study

(2020) A.‐C. Fougerousse et al.   JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY

Real‐life effectiveness and short‐term (16‐week) tolerance of guselkumab for psoriasis: a Belgian retrospective multicentre study

(2020) F. Benhadou et al.   JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY

Psoriasis Pathogenesis and Treatment

(2019) Adriana Rendon et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Drug survival of guselkumab for psoriasis in a real-world setting: a single-center retrospective chart review

(2019) Erica B. Lee et al.   JOURNAL OF DERMATOLOGICAL TREATMENT

Users of Biologics in Clinical Practice: would they be eligible for Phase III Clinical Studies? Cohort Study in the French Psoriasis Registry PSOBIOTEQ

(2019) Marie Masson Regnault et al.   JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY

Psoriatic disease treatment nowadays: unmet needs among the “jungle of biologic drugs and small molecules”

(2018) Matteo Megna et al.   CLINICAL RHEUMATOLOGY

Guselkumab for the treatment of psoriasis

(2018) Matteo Megna et al.   EXPERT OPINION ON BIOLOGICAL THERAPY

Shifting the focus - the primary role of IL-23 in psoriasis and other inflammatory disorders

(2018) M.J. Gooderham et al.   JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY

IL-23 inhibitors for moderate-to-severe psoriasis

(2018) Erin Ibler et al.   SEMINARS IN CUTANEOUS MEDICINE AND SURGERY

Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: Results from the phase III, double-blinded, placebo- and active comparator–controlled VOYAGE 1 trial

(2017) Andrew Blauvelt et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to severe psoriasis with randomized withdrawal and retreatment: Results from the phase III, double-blind, placebo- and active comparator–controlled VOYAGE 2 trial

(2017) Kristian Reich et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY